Redefining Cancer Immunity
Naz Therapeutics seeks medical innovation by developing an anti-FCRLA antibody to restore anti-tumor immunity in B-cell malignancies. Our mission is to provide transformative treatments for patients by supporting T-cell function.
Rethinking Immunity to Create a Better Future
At Naz Therapeutics, Inc., we are dedicated to advancing cancer treatment through targeted immunotherapies. Discover our key areas of focus and how our innovative solutions are making a difference.
Targeting FCRLA
Our primary focus is on the anti-FCRLA antibody, a novel approach designed to specifically target and combat B-cell malignancies. This therapy aims to restore the body's natural anti-tumor immunity by targeting FCRLA and its ability to blind the body's immune cells.
Restoring anti-tumor immunity
We are dedicated to understanding and reversing the mechanisms that allow B-cell malignancies to evade the immune system. Our research centers on reactivating the body's defenses to fight cancer effectively.
